Invivyd IVVD
NASDAQ IVVD
$0.83 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Invivyd (IVVD) Cash from Operations (2021 - 2025)

Invivyd's (IVVD) quarterly Cash from Operations came in at -$15.5 million in Q4 2025, up 58.91% on a YoY basis from -$9.7 million in Q4 2024, and down 87.33% quarter-over-quarter from -$8.2 million in Q3 2025.

Analysis

Invivyd (IVVD) Cash from Operations (2021 - 2025) Analysis & Trends

Invivyd (IVVD) has reported Cash from Operations for 5 consecutive years, with -$15.5 million the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 58.91% year-over-year to -$15.5 million; the trailing twelve-month figure through Dec 2025 stood at -$58.1 million (up 65.9% YoY), and the FY2025 full-year result was -$58.1 million, up 65.9% from the prior year.
  • Cash from Operations fell to -$15.5 million in Q4 2025 per IVVD's latest filing, from -$8.2 million in the prior quarter.
  • Across five years, Cash from Operations topped out at -$8.2 million in Q3 2025 and bottomed at -$73.2 million in Q4 2021.
  • Historically, Cash from Operations has averaged -$40.3 million across 5 years, with a median of -$41.1 million in 2023.
  • The sharpest annual moves came in 2022 and 2025: Cash from Operations sank 148.72% in 2022, then soared 79.91% in 2025.
  • Over 5 years, Cash from Operations stood at -$73.2 million in 2021, then surged by 35.25% to -$47.4 million in 2022, then slipped by 24.97% to -$59.2 million in 2023, then soared by 36.51% to -$37.6 million in 2024, then soared by 58.91% to -$15.5 million in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods registered -$15.5 million, -$8.2 million, and -$13.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 4.00 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 3.57 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 1.13 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 813.00 Mn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn -
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn -526.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 326.72 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 448.90 Mn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn -88.83 Mn
10 Invivyd 244.65 Mn 84.57 Mn 13.01 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -15.46 Mn
Sep 30, 2025 -8.25 Mn
Jun 30, 2025 -13.30 Mn
Mar 31, 2025 -21.13 Mn
Dec 31, 2024 -37.61 Mn
Sep 30, 2024 -41.07 Mn
Jun 30, 2024 -41.60 Mn
Mar 31, 2024 -50.21 Mn
Dec 31, 2023 -59.24 Mn
Sep 30, 2023 -35.35 Mn
Jun 30, 2023 -37.39 Mn
Mar 31, 2023 -41.18 Mn
Dec 31, 2022 -47.40 Mn
Sep 30, 2022 -56.14 Mn
Jun 30, 2022 -57.39 Mn
Mar 31, 2022 -59.05 Mn
Dec 31, 2021 -73.21 Mn
Sep 30, 2021 -54.21 Mn
Jun 30, 2021 -33.57 Mn
Mar 31, 2021 -23.74 Mn